Reconfigurable Metamaterial Structure at Millimeter Wave Frequency Range

In this paper, reconfigurable metamaterial structure at millimeter wave frequency range was designed and simulated for a future fifth generation (5G) mobile-phone beam switching applications. The new proposed structure was composed of a bridge-shaped resonator (BSR) in the front face and strip line at the back face of the unit cell which operates at 28 GHz. First, non-reconfigurable low loss BSR unit cell was designed and subsequently, the reconfigurability was achieved using four switches formed in the gaps of the structure. The proposed structure achieves the lowest loss and almost full transmission among its counterparts by -0.06 dB (0.99 in linear scale). To demonstrate the reconfigurability of the metamaterial, the reflection and transmission coefficients and real parts of the effective refractive index at each reconfigured frequency were studied and investigated. Simulation results showed that a high transmission and reflection peaks occur at each resonance frequency according to change the state of the switches

Dual band low loss metamaterial structure at millimetre wave band

In this paper, the Dual band modified split square resonator (MSSR) metamaterial (MM) structure was designed and numerically investigated at millimetre wave (mm-Wave) frequency range. The proposed structure operated at two resonance frequencies 28 GHz and 32.54 GHz. The dual-band behaviour of the proposed structure because of the self and mutual coupling between two metallic squares of the structure. Furthermore, The MSRR structure performed very well at both resonance frequencies by providing high transmission coefficient, S21, with a loss of -0.3 dB (0.97 linear scale) at lower resonance frequency 28 GHz and -0.18 dB (0.98 linear scale) at upper resonance frequency 32.54 GHz. In this regard, the numerical simulation was conducted to optimize the MSSR structure in such a way that the ratio of effective inductance-to-capacitance (L/C) was raised. As a result, the inherent MM losses were reduced. The robust retrieval algorithm was utilized to reconstruct the refractive index, effective permittivity, and effective permeability and to verify the left-hand property of the proposed structure. The simulation results showed that the MSSR unit cell introduces two regions of the negative refractive index below the lower resonance frequency, 28 GHz and above the upper resonance frequency, 32.54 GHz

Umbelliprenin-coated Fe3O4 magnetite nanoparticles: Antiproliferation evaluation on human Fibrosarcoma cell line (HT-1080)

The potential applications of Fe3O4 magnetite nanoparticles (MNPs) in nanomedicine as drug delivery systems are well known. In this study we prepared umbelliprenin-coated Fe3O4 MNPs and evaluated the antiproliferative effect of combination in vitro. After synthesis of Fe3O4 MNPs, particles were characterized by transmission electron microscopy, energy-dispersive spectroscopy, and X-ray diffraction spectroscopy techniques. The natural candidate compound — umbelliprenin— was isolated and identified and umbelliprenin-coated Fe3O4 MNPs were prepared, using precipitation method. The surface chemistry of umbelliprenin-coated Fe3O4 MNPs as well as their thermal decomposition characteristics was examined using Fourier transform infrared spectroscopy and Thermogravimetric Analyzer equipment, respectively. HT-1080 cells were cultured until the logarithmic phase of growth, and MTT assay was successfully carried out to evaluate the possible cytotoxic effects of umbelliprenin-coated Fe3O4 MNPs in viable cells in vitro. The results demonstrated that umbelliprenin has moderate antiproliferative effects with IC50 value of 50 μg/mL. However, the combination of umbelliprenin and Fe3O4 MNPs showed the IC50 value of 9 μg/mL. In other words, cell proliferation decreased to the remarkably-low proportion of 45% after treating cells with umbelliprenin-coated Fe3O4 MNPs. This suggests that with the aid of nanoparticles as carriers, natural products may have even broader range of medical applications in future

Revalidation and electronic cataract surgery audit: a Scottish survey on current practice and opinion

PURPOSE: To determine current knowledge and opinion on revalidation, and methods of cataract surgery audit in Scotland and to outline the current and future possibilities for electronic cataract surgery audit. METHODS: In 2010 we conducted a prospective, cross-sectional, Scottish-wide survey on revalidation knowledge and opinion, and cataract audit practice among all senior NHS ophthalmologists. Results were anonymised and recorded manually for analysis. RESULTS: In all, 61% of the ophthalmologists surveyed took part. Only 33% felt ready to take part in revalidation, whereas 76% felt they did not have adequate information about the process. Also, 71% did not feel revalidation would improve patient care, but 85% agreed that cataract surgery audit is essential for ophthalmic practice. In addition, 91% audit their cataract outcomes; 52% do so continuously. Further, 63% audit their subspecialist surgical results. Only 25% audit their cataract surgery practice electronically, and only 12% collect clinical data using a hospital PAS system. Funding and system incompatibility were the main reasons cited for the lack of electronic audit setup. Currently, eight separate hospital IT patient administration systems are used across 14 health boards in Scotland. CONCLUSION: Revalidation is set to commence in 2012. The Royal College of Ophthalmologists will use cataract outcome audit as a tool to ensure surgical competency for the process. Retrospective manual auditing of cataract outcome is time consuming, and can be avoided with an electronic system. Scottish ophthalmologists view revalidation with scepticism and appear to have inadequate knowledge of the process. However, they strongly agree with the concept of cataract surgery audit. The existing and future electronic applications that may support surgical audit are commercial electronic records, web-based applications, centrally funded software applications, and robust NHS connections between community and hospital

Governance of microfinance institutions (MFIs) in Cameroon: What lessons can we learn?

The aim of this paper is to find out the effects of the COBAC regulations regulating the microfinance industry on the governance of microfinance institutions (MFIs) in Cameroon. The paper is based on 35 in-depth interviews carried out from May to June 2011 and June to July 2012 with managers and accountants from MFIs in Cameroon, MFI clients and non-clients, regulatory authorities in the Ministry of Finance, and accounting professionals. The findings show that the regulations have broken down the governance within the MFIs in Cameroon thus turning MFIs into hybrid organizations with managers striving to meet their shareholders' interests

The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.

BACKGROUND: The existing estimate of the global burden of latent TB infection (LTBI) as "one-third" of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI. METHODS AND FINDINGS: We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%-26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%-0.9%) of the global population, amounting to 55.5 (95% UI: 48.2-63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI. CONCLUSIONS: We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached

Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa

Few studies from Africa have described the clinical impact of co-infections on SARS-CoV-2 infection. Here, we investigate the presentation and outcome of SARS-CoV-2 infection in an African setting of high HIV-1 and tuberculosis prevalence by an observational case cohort of SARS-CoV-2 patients. A comparator group of non SARS-CoV-2 participants is included. The study includes 104 adults with SARS-CoV-2 infection of whom 29.8% are HIV-1 co-infected. Two or more co-morbidities are present in 57.7% of participants, including HIV-1 (30%) and active tuberculosis (14%). Amongst patients dually infected by tuberculosis and SARS-CoV-2, clinical features can be typical of either SARS-CoV-2 or tuberculosis: lymphopenia is exacerbated, and some markers of inflammation (D-dimer and ferritin) are further elevated (p < 0.05). Amongst HIV-1 co-infected participants those with low CD4 percentage strata exhibit reduced total, but not neutralising, anti-SARS-CoV-2 antibodies. SARS-CoV-2 specific CD8 T cell responses are present in 35.8% participants overall but undetectable in combined HIV-1 and tuberculosis. Death occurred in 30/104 (29%) of all COVID-19 patients and in 6/15 (40%) of patients with coincident SARS-CoV-2 and tuberculosis. This shows that in a high incidence setting, tuberculosis is a common co-morbidity in patients admitted to hospital with COVID-19. The immune response to SARS-CoV-2 is adversely affected by co-existent HIV-1 and tuberculosis

Performance evaluation of damper control settings for operation of multiple-zone variable air volume reheat system in different building applications and climate types

Choosing the right control strategies is an important task for effective operation of variable air volume reheat (VAVR) system in commercial buildings. In this design, dampers’ position inside air terminal units (ATUs) are modulated to adjust the amount of air supply volume based on thermal zones’ cooling or heating demand. A minimum air flow fraction (MAFF) is set for damper settings of ATUs to avoid under-ventilation problem in thermal zones. This study investigated the impact of MAFF value on various performance aspects of multiple-zone VAVR design in different building applications and climate types. A five-storey commercial building for three applications of school, office and retail in four climate types of tropical monsoon, hot desert, Mediterranean and humid continental have been simulated in EnergyPlus building simulation software. The results of simulations have shown that lowering MAFF value in ATUs would reduce the required reheat coil energy to maintain precise air supply temperature at part load cooling scenarios. Nonetheless, this reduction could have some implications on thermal comfort and indoor air quality level of thermal zones in a multiple-zone arrangement. It was concluded that in general it is an energy efficient control strategy to keep MAFF value to as low as 0.1 for high ventilation rate spaces like classrooms in school buildings (except for hot desert climate). On the other hand, it is advisable to not reduce MAFF value below 0.3 for low ventilation rate spaces like office areas to avoid any air quality issues in thermal zones

Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins

BACKGROUND: Mesenchymal stem cells (MSC) are promising candidates for cell therapy, as they migrate to areas of injury, differentiate into a broad range of specialized cells, and have immunomodulatory properties. However, MSC are not invisible to the recipient's immune system, and upon in vivo administration, allogeneic MSC are able to trigger immune responses, resulting in rejection of the transplanted cells, precluding their full therapeutic potential. Human cytomegalovirus (HCMV) has developed several strategies to evade cytotoxic T lymphocyte (CTL) and Natural Killer (NK) cell recognition. Our goal is to exploit HCMV immunological evasion strategies to reduce MSC immunogenicity. METHODOLOGY/PRINCIPAL FINDINGS: We genetically engineered human MSC to express HCMV proteins known to downregulate HLA-I expression, and investigated whether modified MSC were protected from CTL and NK attack. Flow cytometric analysis showed that amongst the US proteins tested, US6 and US11 efficiently reduced MSC HLA-I expression, and mixed lymphocyte reaction demonstrated a corresponding decrease in human and sheep mononuclear cell proliferation. NK killing assays showed that the decrease in HLA-I expression did not result in increased NK cytotoxicity, and that at certain NK∶MSC ratios, US11 conferred protection from NK cytotoxic effects. Transplantation of MSC-US6 or MSC-US11 into pre-immune fetal sheep resulted in increased liver engraftment when compared to control MSC, as demonstrated by qPCR and immunofluorescence analyses. CONCLUSIONS AND SIGNIFICANCE: These data demonstrate that engineering MSC to express US6 and US11 can be used as a means of decreasing recognition of MSC by the immune system, allowing higher levels of engraftment in an allogeneic transplantation setting. Since one of the major factors responsible for the failure of allogeneic-donor MSC to engraft is the mismatch of HLA-I molecules between the donor and the recipient, MSC-US6 and MSC-US11 could constitute an off-the-shelf product to overcome donor-recipient HLA-I mismatch